Concepedia

Andrew Calinisan

AC

Statistics

Publications

8

Citations

2.7K

H-Index

8

Active since

2019

Affiliations

Mirati Therapeutics (United States)(Current)

Bell Biosystems (United States)

Pfizer (United States)

Array BioPharma (United States)

Andrew Calinisan is an author at Mirati Therapeutics (United States) specializing in oncology, medicine, and cancer pharmacology.

ORCID

Publications per year

2019–2025

8

Publications

8

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

, , +17

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

, , +14

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

, , +9

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics · 2021 · 167 citations · Full text

, , +17

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos et al. · Molecular Cancer Therapeutics · 2024 · 32 citations · Full text

, , +14

1–5 of 8